22 July 2021 - Submits supplemental new drug application to the U.S. FDA for Oxbryta (voxelotor) in children with SCD ages 4 to 11.
Global Blood Therapeutics today announced updates across several of its development programs in sickle cell disease.
The company has submitted a supplemental new drug application to the U.S. FDA seeking accelerated approval for Oxbryta (voxelotor) for the treatment of sickle cell disease in children ages 4 to 11 years, together with a related separate new drug application required to seek approval for a paediatric weight-based formulation of Oxbryta.